

Noah Boton MD, Jiaqi Ni, Anthony Mack, Gregory Eschenauer, PharmD, BCPS (AQ-ID) Twisha Patel, BCPS, BCIDP, John Y. Kao, MD, Krishna Rao, MD, MS University of Michigan Hospital, Ann Arbor, MI

### Background

- Recurrent *C. difficile* infection (CDI) is common following recovery from CDI.
- Fecal microbiota transplantation (FMT) is highly effective for treatment of recurrent CDI.
- FMT is generally safe, though there are serious risks to consider.



- We performed a retrospective cohort study of all patients at a large academic center who received their first FMT for recurrent CDI.
- Outcomes included recurrent CDI and persistent non-CDI related diarrhea within 90 days of FMT.
- Statistical analysis was performed with unadjusted and adjusted logistic regression.

## **Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent** Clostridioides difficile Infection

# Conclusions **FMT** is effective for treatment of recurrent CDI.

## Patients with higher BMI and longer duration of antibiotic therapy prior to FMT may be protected against recurrence.

Patients with a history of IBS are more likely to have persistent diarrhea following FMT that is not due to CDI.

Table 3: Multivariable models of adverse outcomes following FMT for CDI							
	<b>Recurrent CDI</b>		Persistent diarrhea				
	OR [95% CI]	Ρ	OR [95% CI]	Ρ			
Age, years	—	-	0.98 [0.95,1.01]	.185			
BMI, kg/m <sup>2</sup>	0.73 [0.52,0.92]	.028	-	-			
IBS	-	-	6.16 [1.39,34.2]	.022			
<b># CDI episodes prior to FMT</b>	-	-	0.68 [0.42,1.05]	.096			
Duration of antibiotic therapy	0.36 [0.12,0.88]	.038	-	-			
for CDI prior to FMT, log(days)							
Abbreviations: CDI, Clostridioides difficile infection; CI, confidence interval; FMT, fecal microbiota transplantation; IBS, irritable bowel							
syndrome; OR, odds ratio.							

	Table 1	: Patient charact	teristics (n=81)		
	Age, yr	(median, IQR)	58 (41-72)		
	Female	e sex	52 (64%)		
	BMI, kg	ŋ∕m²	25.63 ± 7.14		
	IBS		13 (16%)		
	IBD		10 (12%)		
	# CDI e	pisodes	3.8 ± 1.3		
	Route	of FMT:			
	Lower GI delivery		10 (12%)		
	Capsules		71 (88%)		
	•	1. Longth of antik	nintic therapy for CDI prior		
	•	1: Length of antik	biotic therapy for CDI prior		
	Figure	1: Length of antik	biotic therapy for CDI prior		
S	Figure to FMT 30	1: Length of antik	biotic therapy for CDI prior		
atients	Figure to FMT 30	1: Length of antik	biotic therapy for CDI prior		
# Patients	Figure to FMT 30	1: Length of antik	biotic therapy for CDI prior		
# Patients	Figure to FMT 30	1: Length of antik	biotic therapy for CDI prior		
# Patients	Figure to FMT30252015	1: Length of antik	biotic therapy for CDI prior		
# Patients	Figure to FMT3002552001151005	1: Length of antik	biotic therapy for CDI prior		
# Patients	Figure   300   200   115   100		biotic therapy for CDI prior		

Recuri
Persis diarrhe
<sup>1</sup> Percenta <sup>2</sup> Percenta
Table 4 diarrhe
IBS/po IBD
SIBO Radiat
No cle

Table 2



#### Results



Length of antibiotic therapy (Days)				
2: Outcomes (within 90 days of FMT)				
rent CDI	<b>9 (11%)</b> <sup>1</sup>			
tent non-CDI related	<b>26 (36%)</b> <sup>2</sup>			
ea				
ige of all patients ige of patients without recurrent CDI				
4: Etiologies for persistent non-CDI related ea following FMT (n=26)				
st-infectious IBS	10 (38%)			
	4 (15%)			
	<b>2</b> /00/ \			

	2 (8%)
tion colitis/proctitis	1 (4%)
ear etiology	9 (35%)